Dr. Shanahan, 68, served as the Chief Medical Officer of Arena Pharmaceuticals, Inc., from 2004 to June 2016 and served as its Senior Vice President from June 2010 to June 2016. Dr. Shanahan also served as Vice President of Arena Pharmaceuticals Inc. from March 2004 to June 2010.
At Arena Pharmaceuticals Inc., Dr. Shanahan was involved in all aspects of preclinical and clinical development, from phase 1 through NDA filing and approval, of lorcaserin, a selective 5-HT2C agonist for weight management, as well as multiple other programs in a range of therapeutic areas through phase 1 and phase 2.
He served as Tanox Inc.’s Chief Medical Officer from August 2000 until March 2004, developing several monoclonal antibodies for allergy, inflammation and HIV through phase 1 and phase 2.
Dr. Shanahan served as Vice President, Drug Development of Isis Pharmaceuticals from 1994 to August 2000, working on anti-inflammatory/immunomodulatory antisense therapeutics in phase 1-3. Prior to that, he was Director of Clinical Research at Pfizer Central Research where he directed the clinical development of new anti-inflammatory pharmacologic agents from 1990 to 1994.
At Searle Research and Development, he held Associate Director and Director of Clinical Research positions where he developed and monitored clinical studies related to anti-inflammatory, gastro-protective, anti-HIV, and antineoplastic pharmacologic agents from 1988 to 1990. In addition, at the University of Connecticut School of Medicine he held various positions in the Division of Rheumatology including a full time faculty position as Assistant Professor and a voluntary and part-time position as Clinical Associate Professor.
Dr. Shanahan holds an A.B. degree from Dartmouth College, an M.D. degree from the University of California, San Francisco, and a J.D. degree from Loyola University, Chicago.